Across TCGA pan-cancer cohorts, FTL Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FTL data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher FTL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FTL expression acts as an unfavorable survival marker.
STAD and KIRP are the cancer types where FTL Mutation most reproducibly stratifies survival.